[{"address1": "1901 West 47th Place", "city": "Kansas City", "state": "KS", "zip": "66205", "country": "United States", "phone": "913 942 2300", "website": "https://www.cingulate.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.", "fullTimeEmployees": 13, "companyOfficers": [{"maxAge": 1, "name": "Dr. Shane J. Schaffer Pharm.D.", "age": 48, "title": "CEO & Chairman of the Board", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 491961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Laurie A. Myers M.B.A., Ph.D.", "age": 66, "title": "Executive VP & COO", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 415167, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew N. Brams M.D.", "age": 59, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 244792, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer L. Callahan CPA", "age": 52, "title": "Senior VP, CFO & Secretary", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raul R. Silva M.D.", "age": 65, "title": "Executive VP & Chief Science Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Thomas  Dalton", "title": "Vice President of Investor & Public Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.49, "open": 4.41, "dayLow": 4.41, "dayHigh": 4.6, "regularMarketPreviousClose": 4.49, "regularMarketOpen": 4.41, "regularMarketDayLow": 4.41, "regularMarketDayHigh": 4.6, "beta": -0.934, "forwardPE": -0.627907, "volume": 50375, "regularMarketVolume": 50375, "averageVolume": 3891289, "averageVolume10days": 114550, "averageDailyVolume10Day": 114550, "marketCap": 13972695, "fiftyTwoWeekLow": 1.8, "fiftyTwoWeekHigh": 152.4, "fiftyDayAverage": 6.153, "twoHundredDayAverage": 14.09037, "currency": "USD", "enterpriseValue": 4312332, "floatShares": 947664, "sharesOutstanding": 3044160, "sharesShort": 27862, "sharesShortPriorMonth": 204945, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0092, "heldPercentInsiders": 0.03482, "heldPercentInstitutions": 0.02705, "shortRatio": 0.05, "shortPercentOfFloat": 0.0095, "impliedSharesOutstanding": 3044160, "bookValue": 3.95, "priceToBook": 1.1620253, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -19095904, "trailingEps": -326.4, "forwardEps": -7.31, "lastSplitFactor": "1:12", "lastSplitDate": 1723161600, "enterpriseToEbitda": -0.239, "52WeekChange": -0.9609694, "SandP52WeekChange": 0.39070773, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CING", "underlyingSymbol": "CING", "shortName": "Cingulate Inc.", "longName": "Cingulate Inc.", "firstTradeDateEpochUtc": 1638973800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bf898f9d-c1c1-3f31-9c96-a5b2c0f73dcd", "messageBoardId": "finmb_1674914781", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.59, "targetHighPrice": 96.0, "targetLowPrice": 70.0, "targetMeanPrice": 80.33, "targetMedianPrice": 75.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 380928, "totalCashPerShare": 0.401, "ebitda": -18046852, "totalDebt": 330438, "quickRatio": 0.997, "currentRatio": 1.231, "debtToEquity": 10.715, "returnOnAssets": -2.25765, "freeCashflow": -12054312, "operatingCashflow": -17342736, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-21"}]